“Drug Delivery Technologies market set to grow to $355bn by 2024” says new Visiongain report

28 February 2019
Pharma

Visiongain has published a new pharma report Drug Delivery Technologies Market Forecast : Oral, Inhalable, Injectable/Implantable, Transdermal, Ocular, Nasal/Buccal Drug Delivery Technologies, Biologics, Vaccines.

The Drug Delivery Technologies Market is estimated to grow at a CAGR of 7.8% from 2019 to 2029, driven by exciting new technologies and the potential of extending product life by developing new formulations.

Over the last ten years, the global drug delivery technologies market has witnessed a significant increase in the number of drug delivery companies offering innovative technologies to pharmaceutical manufacturers. Drug delivery technology is an important enabling technology for pharmaceutical products. These platforms are often used by pharmaceutical companies for various reasons, which importantly include the extension of product lifecycle.

There are companies developing new technologies to take advantage of the potential for growth that is abundant in this market. This rapidly expanding market provides growth opportunities for developers willing to invest in R&D. This report profiled the selected companies: 3M, Alkermes PLC, Altea Therapeutics Corporation, Antares Pharma Inc., Applied Pharma Research S.A. (APR), Becton, Dickinson & Company and others.

The lead analyst commented that "The potential use of drug delivery technologies in product lifecycle management and the enhancement of drug efficacy in many therapeutic sectors will act as drivers for growth of the market over the coming decade. This is mainly due to the rising demand from pharmaceutical companies looking to innovate and improve the marketability of their drugs. The potential of extending the patent life of a drug by developing new formulations will act as a driver for the market as it will prompt pharma companies to seek to maximise the return on investment from each marketed drug."

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Biopharmaceuticals Contract Manufacturing Market Report 2022-2032

Ageing population will be more susceptible to such diseases and is one of the key factors driving the growth of the global biological drugs market. In most of the developed world, the share of elderly population is almost touching a quarter of the population.

26 January 2022

Read

Visiongain Publishes Topical Drug Delivery Market Report 2022-2032

Some of the factors driving the market growth are the increasing prevalence of skin and eye diseases, high incidences of burn incidences and the growing prevalence of diabetes.

26 January 2022

Read

Visiongain Publishes Decentralized Clinical Trials Market Report 2022-2032

The growing adoption advanced e-clinical solutions, rising focus on clinical research, increasing investment in R&D, and adoption of decentralized clinical trials by biopharmaceutical companies are some of the major factors that drive the growth of the global decentralized clinical trials market.

24 January 2022

Read

Visiongain Publishes Nasal Drug Delivery Technology Market Report 2022-2032

The nasal drug delivery market will expand rapidly due to rising patient preference for nasal medication delivery due to ease of administration and efficacy, increased self-administration practises, and increased demand for home healthcare equipment.

18 January 2022

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever